E D Roberson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Frontotemporal dementia progresses to death faster than Alzheimer disease
    E D Roberson
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Neurology 65:719-25. 2005
  2. ncbi request reprint Frontotemporal dementia
    Erik D Roberson
    Memory and Aging Center, Department of Neurology, University of California San Francisco, 1650 Owens Street, San Francisco, CA 94158, USA
    Curr Neurol Neurosci Rep 6:481-9. 2006
  3. ncbi request reprint Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model
    Erik D Roberson
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Science 316:750-4. 2007
  4. pmc Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease
    William J Meilandt
    Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA
    J Neurosci 28:5007-17. 2008
  5. ncbi request reprint Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease
    Sarah Mueller-Steiner
    Gladstone Institute of Neurological Disease, University of California, San Francisco, 1650 Owens Street, 94158, USA
    Neuron 51:703-14. 2006
  6. ncbi request reprint Abnormal social behaviors in mice lacking Fgf17
    K Scearce-Levie
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158 2261, USA
    Genes Brain Behav 7:344-54. 2008
  7. ncbi request reprint Frontotemporal lobar degeneration: demographic characteristics of 353 patients
    Julene K Johnson
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, 94117, USA
    Arch Neurol 62:925-30. 2005
  8. ncbi request reprint Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease
    Jorge J Palop
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Neuron 55:697-711. 2007
  9. pmc 100 years and counting: prospects for defeating Alzheimer's disease
    Erik D Roberson
    Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94158, USA
    Science 314:781-4. 2006

Research Grants

Detail Information

Publications9

  1. ncbi request reprint Frontotemporal dementia progresses to death faster than Alzheimer disease
    E D Roberson
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Neurology 65:719-25. 2005
    ..Frontotemporal lobar degeneration (FTLD) is a common cause of non-Alzheimer dementia, but its natural history and the factors related to mortality in affected patients are not well understood...
  2. ncbi request reprint Frontotemporal dementia
    Erik D Roberson
    Memory and Aging Center, Department of Neurology, University of California San Francisco, 1650 Owens Street, San Francisco, CA 94158, USA
    Curr Neurol Neurosci Rep 6:481-9. 2006
    ....
  3. ncbi request reprint Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model
    Erik D Roberson
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Science 316:750-4. 2007
    ..Thus, tau reduction can block Abeta- and excitotoxin-induced neuronal dysfunction and may represent an effective strategy for treating Alzheimer's disease and related conditions...
  4. pmc Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease
    William J Meilandt
    Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA
    J Neurosci 28:5007-17. 2008
    ..We conclude that enkephalin elevations may contribute to cognitive impairments in hAPP mice and possibly in humans with AD. The therapeutic potential of reducing enkephalin production or signaling merits further exploration...
  5. ncbi request reprint Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease
    Sarah Mueller-Steiner
    Gladstone Institute of Neurological Disease, University of California, San Francisco, 1650 Owens Street, 94158, USA
    Neuron 51:703-14. 2006
    ..Thus, CatB likely fulfills antiamyloidogenic and neuroprotective functions. Insufficient CatB activity might promote AD; increasing CatB activity could counteract the neuropathology of this disease...
  6. ncbi request reprint Abnormal social behaviors in mice lacking Fgf17
    K Scearce-Levie
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158 2261, USA
    Genes Brain Behav 7:344-54. 2008
    ..Our findings show that Fgf17 is required for several complex social behaviors and suggest that disturbances in Fgf17 signaling may contribute to neuropsychiatric diseases that affect such behaviors...
  7. ncbi request reprint Frontotemporal lobar degeneration: demographic characteristics of 353 patients
    Julene K Johnson
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, 94117, USA
    Arch Neurol 62:925-30. 2005
    ..The publication of consensus criteria for FTLD, however, prompted systematic studies. The criteria categorize FTLD into 3 subgroups: frontotemporal dementia, semantic dementia, and progressive nonfluent aphasia...
  8. ncbi request reprint Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease
    Jorge J Palop
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Neuron 55:697-711. 2007
    ..Aberrant increases in network excitability and compensatory inhibitory mechanisms in the hippocampus may contribute to Abeta-induced neurological deficits in hAPP mice and, possibly, also in humans with AD...
  9. pmc 100 years and counting: prospects for defeating Alzheimer's disease
    Erik D Roberson
    Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94158, USA
    Science 314:781-4. 2006
    ..The predicted increase in AD cases over the next few decades makes the development of better treatments a matter of utmost importance and urgency...

Research Grants1

  1. Mechanisms for Tau Involvement in Alzheimer's Disease
    ERIK ROBERSON; Fiscal Year: 2007
    ..The mentoring and research experience described in this proposal will facilitate the candidate's goal of an independent faculty research position. ..